Lantern Pharma Inc.
LTRN
$3.59
-$0.03-0.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 11.21% | -3.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.84% | -4.23% | |||
| Operating Income | -13.84% | 4.23% | |||
| Income Before Tax | -30.39% | 9.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.39% | 9.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.39% | 9.15% | |||
| EBIT | -13.84% | 4.23% | |||
| EBITDA | -13.85% | 4.24% | |||
| EPS Basic | -29.00% | 9.20% | |||
| Normalized Basic EPS | -24.16% | 9.20% | |||
| EPS Diluted | -29.00% | 9.20% | |||
| Normalized Diluted EPS | -24.16% | 9.20% | |||
| Average Basic Shares Outstanding | 1.08% | 0.04% | |||
| Average Diluted Shares Outstanding | 1.08% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||